![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Naive Adults With HIV-1 and High Baseline Viral Load (VL): 48-Week Subgroup Analyses of the GEMINI-1/-2 and STAT Trials
|
|
|
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Charlotte-Paige Rolle,1 José R. Arribas,2 Roberto Ortiz,3 Jessica Matthews,4 Choy Man,4 Richard Grove,5 Cynthia Donovan,4 Brian Wynne,4 Michelle Kisare,6 Bryn Jones7
1Orlando Immunology Center, Orlando, FL, USA; 2Hospital Universitario La Paz, Madrid, Spain; 3Bliss Healthcare Services, Orlando, FL, USA; 4ViiV Healthcare, Durham, NC, USA; 5GSK, Brentford, UK;
6GSK, Nairobi, Kenya; 7ViiV Healthcare, Brentford, UK
![1028221](../images/102822/102822-3/1028221.gif)
![1028222](../images/102822/102822-3/1028222.gif)
![1028223](../images/102822/102822-3/1028223.gif)
![1028224](../images/102822/102822-3/1028224.gif)
![1028225](../images/102822/102822-3/1028225.gif)
![1028226](../images/102822/102822-3/1028226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|